Jump to main content
Jump to site search

Issue 2, 2016
Previous Article Next Article

Antimicrobial activity of levofloxacin – M33 peptide conjugation or combination

Author affiliations

Abstract

M33 is a branched peptide currently under preclinical characterization for development as a new drug against Gram-negative bacteria. Here we report its antibacterial activity in conjugation or combination with levofloxacin (LVFX), a fluoroquinolone antibiotic. Antibacterial assays showed no significant differences in activity when used in conjugation, while the combination of M33 and LVFX showed improved activity against Gram-negative bacteria. Combination treatment therefore opposes antimicrobial-resistance, restoring the effect of LVFX.

Graphical abstract: Antimicrobial activity of levofloxacin – M33 peptide conjugation or combination

Back to tab navigation

Publication details

The article was received on 08 Sep 2015, accepted on 14 Nov 2015 and first published on 19 Nov 2015


Article type: Research Article
DOI: 10.1039/C5MD00392J
Citation: Med. Chem. Commun., 2016,7, 258-262
  •   Request permissions

    Antimicrobial activity of levofloxacin – M33 peptide conjugation or combination

    F. Ceccherini, C. Falciani, M. Onori, S. Scali, S. Pollini, G. M. Rossolini, L. Bracci and A. Pini, Med. Chem. Commun., 2016, 7, 258
    DOI: 10.1039/C5MD00392J

Search articles by author

Spotlight

Advertisements